Wells Fargo Upgrades Watson Pharmaceuticals (WPI) to Outperform; Actavis Acquisition Adds Growth Prospects

May 24, 2012 7:24 AM EDT Send to a Friend
Get Alerts WPI Hot Sheet
Price: $85.73 --0%

Rating Summary:
    14 Buy, 5 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 29 | Down: 28 | New: 24
Trade WPI Now!
Join SI Premium – FREE
Wells Fargo upgraded Watson Pharmaceuticals (NYSE: WPI) from Market Perform to Outperform, raising price target range from $75-79 to $84-90.

Analyst, Michael Tong, said, "We have had a positive outlook on WPI's proposed Actavis acquisition. However, we were concerned about lofty 2013 cash EPS expectation (about $8) for Newco, and the share price immediately following the Actavis announcement left very little margin for error in our view. Upon further analysis, we are now more comfortable with Newco's ability to approach the EPS expectation. With WPI shares having pulled back since then, we think the reward/risk profile has turned sufficiently favorable to warrant an upgrade."

Tong raises FY13 EPS (standalone) estimate from $6.05 to $6.22...believe Newco should be able to approach the $8 EPS expectation in 2013.

For an analyst ratings summary and ratings history on Watson Pharmaceuticals click here. For more ratings news on Watson Pharmaceuticals click here.

Shares of Watson Pharmaceuticals closed at $70.71 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst EPS Change, Analyst EPS View, Analyst PT Change, Upgrades

Related Entities

Wells Fargo

Add Your Comment